48m
Toragen, Inc. Announces $12 Million Convertible Note Financing and Expansion of Board of Directors
Toragen, Inc., a clinical-stage biotechnology company developing a first-in-class, oral small molecule HPV E5 protein inhibitor targeting cancers caused by the human papillomavirus ("HPV"), today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback